Click for best price
Human Immunodeficiency Virus HIV1 Therapeutics Market Size, Share 2023
| Market size in 2022 |
US$ 12220 million
|
Forecast Market size by 2029 |
US$ 12890 million
|
| Growth Rate |
CAGR of 0.8% |
Number of Pages |
67 Pages |
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
This report aims to provide a comprehensive presentation of the global market for Human Immunodeficiency Virus (HIV)-1 Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Immunodeficiency Virus (HIV)-1 Therapeutics. This report contains market size and forecasts of Human Immunodeficiency Virus (HIV)-1 Therapeutics in global, including the following market information:
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market was valued at US$ 12220 million in 2022 and is projected to reach US$ 12890 million by 2029, at a CAGR of 0.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
We surveyed the Human Immunodeficiency Virus (HIV)-1 Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, by Type, 2022 (%)
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Labs
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Immunodeficiency Virus (HIV)-1 Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Human Immunodeficiency Virus (HIV)-1 Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Immunodeficiency Virus (HIV)-1 Therapeutics, market overview.
Chapter 2: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Human Immunodeficiency Virus (HIV)-1 Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Immunodeficiency Virus (HIV)-1 Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 12220 million
|
| Forecast Market size by 2029 |
US$ 12890 million
|
| Growth Rate |
CAGR of 0.8% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
67 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Overall Market Size
2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size: 2022 VS 2029
2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players in Global Market
3.2 Top Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies Ranked by Revenue
3.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Markets, 2022 & 2029
4.1.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
4.1.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
4.1.4 Entry and Fusion Inhibitors
4.1.5 Protease Inhibitors (PIs)
4.1.6 Integrase Inhibitors
4.1.7 Coreceptor Antagonists
4.2 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2024-2029
4.2.3 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Labs
5.2 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2024-2029
5.2.3 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2022 & 2029
6.2 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2024-2029
6.2.3 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2029
6.3.2 US Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.3.3 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.3.4 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2029
6.4.2 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4.3 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4.4 U.K. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4.5 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4.6 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4.7 Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.4.8 Benelux Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2029
6.5.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.5.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.5.4 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.5.5 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.5.6 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2029
6.6.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.6.3 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2029
6.7.2 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.7.3 Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.7.4 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
6.7.5 UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2018-2029
7 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies Profiles
7.1 AbbVie, Inc.(U.S.)
7.1.1 AbbVie, Inc.(U.S.) Company Summary
7.1.2 AbbVie, Inc.(U.S.) Business Overview
7.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
7.1.4 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2018-2023)
7.1.5 AbbVie, Inc.(U.S.) Key News & Latest Developments
7.2 Merck & Co., Inc. (U.S.)
7.2.1 Merck & Co., Inc. (U.S.) Company Summary
7.2.2 Merck & Co., Inc. (U.S.) Business Overview
7.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
7.2.4 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Merck & Co., Inc. (U.S.) Key News & Latest Developments
7.3 Bristol-Myers Squibb Company (U.S.)
7.3.1 Bristol-Myers Squibb Company (U.S.) Company Summary
7.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
7.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
7.3.4 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Bristol-Myers Squibb Company (U.S.) Key News & Latest Developments
7.4 Boehringer Ingelheim GmbH (Germany)
7.4.1 Boehringer Ingelheim GmbH (Germany) Company Summary
7.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
7.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
7.4.4 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Boehringer Ingelheim GmbH (Germany) Key News & Latest Developments
7.5 Genentech, Inc. (U.S.)
7.5.1 Genentech, Inc. (U.S.) Company Summary
7.5.2 Genentech, Inc. (U.S.) Business Overview
7.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
7.5.4 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Genentech, Inc. (U.S.) Key News & Latest Developments
7.6 Cipla, Inc. (India)
7.6.1 Cipla, Inc. (India) Company Summary
7.6.2 Cipla, Inc. (India) Business Overview
7.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
7.6.4 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Cipla, Inc. (India) Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Opportunities & Trends in Global Market
Table 2. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers in Global Market
Table 3. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints in Global Market
Table 4. Key Players of Human Immunodeficiency Virus (HIV)-1 Therapeutics in Global Market
Table 5. Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Type
Table 9. List of Global Tier 1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2024-2029
Table 30. AbbVie, Inc.(U.S.) Company Summary
Table 31. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings
Table 32. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. AbbVie, Inc.(U.S.) Key News & Latest Developments
Table 34. Merck & Co., Inc. (U.S.) Company Summary
Table 35. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings
Table 36. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Merck & Co., Inc. (U.S.) Key News & Latest Developments
Table 38. Bristol-Myers Squibb Company (U.S.) Company Summary
Table 39. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings
Table 40. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Bristol-Myers Squibb Company (U.S.) Key News & Latest Developments
Table 42. Boehringer Ingelheim GmbH (Germany) Company Summary
Table 43. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings
Table 44. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Boehringer Ingelheim GmbH (Germany) Key News & Latest Developments
Table 46. Genentech, Inc. (U.S.) Company Summary
Table 47. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings
Table 48. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Genentech, Inc. (U.S.) Key News & Latest Developments
Table 50. Cipla, Inc. (India) Company Summary
Table 51. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings
Table 52. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Cipla, Inc. (India) Key News & Latest Developments
List of Figures
Figure 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Type in 2022
Figure 2. Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Application in 2022
Figure 3. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2022
Figure 8. By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 16. US Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 20. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 21. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 28. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 32. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 34. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2018-2029
Figure 37. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US$, Mn), 2018-2029
Figure 41. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
